NDAORALTABLETPriority Review
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
17
Data completeness
6/8 — Strong
Priority Review
PYRUKYND (mitapivat) by Agios Pharmaceuticals is pyruvate kinase activators [moa]. Approved for pyruvate kinase deficiency, beta-thalassemia, alpha-thalassemia. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PYRUKYND (mitapivat) is an oral pyruvate kinase activator approved in February 2022 for treating anemia in adults with alpha- and beta-thalassemia. It works by activating pyruvate kinase to increase red blood cell energy and lifespan, reducing the hemolytic anemia characteristic of thalassemia.
$0.004BPart D
Peak15.2 years to LOEProduct is in peak phase with modest Part D uptake (163 claims in 2023), indicating early commercial traction in a niche orphan indication with room for market expansion.
Mechanism of Action
Pyruvate Kinase Activators
Pharmacologic Class:
Pyruvate Kinase Activator
Indications (3)
Worked on PYRUKYND at Agios Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.